Dean Fennell initially qualified with a first class degree in Pharmacology followed by Medicine and Surgery from University College London. After basic specialist training at UCL, Hammersmith, Brompton, Guy’s and St Thomas’ Hospitals in London he obtained Membership of the Royal College of Physicians, followed by a PhD in Oncology as a MRC Clinical research fellow in UCL.
He completed training in Medical Oncology at St Bartholomew’s Hospital, and then undertook back-to-back Cancer Research UK Clinician Scientist Fellowships, until his current appointment in 2012. He was elected fellow of the Royal College of Physicians (London) in 2007.
He served two terms on the board of the EORTC, leads a translational research laboratory and international clinical trials portfolio focused on translating novel precision medicine strategies from the lab to the clinic. He chief investigator for the CONFIRM, VIM and MiST trials in relapsed mesothelioma, a member of the IASLC & European mesothelioma taskforce, past IMIG president/NCRI mesothelioma CSG chair.
He is currently director of the new Leicester Mesothelioma Research Institute focused on advancing experimental therapy for mesothelioma. Prof. Fennell has over 100 publications in journals including Nature, Nature Reviews Cancer, New England Journal of Medicine, Lancet, Lancet Oncology, Proceedings of the National Academy of Science, Nature Communications, and Journal of the National Cancer Institute.